Despite periodic reports that biosimilars have finally arrived and will save the U.S. health care system billions of dollars, Peter Bach and Mark Trusheim remain unconvinced.
So the high-profile skeptics have refreshed their controversial, two-year-old argument for overhauling the approach for making alternative versions of pricey biologic medicines available to the American public.
Their basic premise remains the same: prices for brand-name biologic medicines should be based on production costs, and manufacturers should be given a fixed profit of 10% to 20% once the standard 12-year exclusive marketing period has ended. But to hammer home their point, they commissioned a report that indicates total savings could hit $360 billion by 2025, nearly four times what might otherwise be saved.
About the Author Reprints
